ArticleSynthetic and systems biotechnology2019
Article in Synthetic and systems biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Optimization of abamectin production by Streptomyces avermitilis and its antagonistic activity against Meloidogyne incognita.BMC biotechnology · 2026Article
- Streptomyces avermitilis MICNEMA2022: a new biorational strain for producing abamectin as an integrated nematode management agent.BMC microbiology · 2024Article
- Potential ofMetabolites · 2024Review
- Enhancement of acyl-CoA precursor supply for increased avermectin B1a production by engineering meilingmycin polyketide synthase and key primary metabolic pathway genes.Microbial biotechnology · 2024Article
- Pharmacokinetics of tenvermectin in swine, a novel antiparasitic drug candidate-comparison with ivermectin.Veterinary medicine and science · 2023Article
- Broadening the spectrum of ivermectin: Its effect onFrontiers in cellular and infection microbiology · 2022Article
- Review
- Streptomycetes as platform for biotechnological production processes of drugs.Applied microbiology and biotechnology · 2021Review
- A roadmap to engineering antiviral natural products synthesis in microbes.Current opinion in biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ivermectin, a kind of valuable derivatives of Avermectin, is distinct from Avermectin due to the saturated bond at C22-C23 position. Combinatorial biosynthesis of Ivermectins based on Avermectins biosynthetic gene cluster (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.